Genomic Health, Inc. (GHDX) COO G Bradley Cole Sells 5,000 Shares of Stock

Genomic Health, Inc. (NASDAQ:GHDX) COO G Bradley Cole sold 5,000 shares of Genomic Health stock in a transaction on Tuesday, September 12th. The stock was sold at an average price of $31.86, for a total transaction of $159,300.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

G Bradley Cole also recently made the following trade(s):

  • On Tuesday, August 8th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The stock was sold at an average price of $30.57, for a total transaction of $152,850.00.
  • On Tuesday, July 11th, G Bradley Cole sold 5,000 shares of Genomic Health stock. The stock was sold at an average price of $32.53, for a total transaction of $162,650.00.

Shares of Genomic Health, Inc. (GHDX) traded up 0.87% during trading on Friday, hitting $31.27. 225,418 shares of the company were exchanged. The company has a 50 day moving average of $30.90 and a 200-day moving average of $31.60. Genomic Health, Inc. has a 1-year low of $26.37 and a 1-year high of $33.97. The stock’s market capitalization is $1.08 billion.

Genomic Health (NASDAQ:GHDX) last released its quarterly earnings data on Tuesday, August 1st. The medical research company reported ($0.08) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.02). Genomic Health had a negative return on equity of 4.33% and a negative net margin of 1.50%. The business had revenue of $85.50 million during the quarter, compared to the consensus estimate of $86.08 million. During the same quarter in the previous year, the business posted ($0.18) earnings per share. Genomic Health’s quarterly revenue was up 4.3% compared to the same quarter last year. On average, analysts forecast that Genomic Health, Inc. will post ($0.01) earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Genomic Health, Inc. (GHDX) COO G Bradley Cole Sells 5,000 Shares of Stock” was first reported by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international trademark & copyright laws. The correct version of this report can be read at https://www.chaffeybreeze.com/2017/09/15/genomic-health-inc-ghdx-coo-g-bradley-cole-sells-5000-shares-of-stock.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Wetherby Asset Management Inc. increased its holdings in Genomic Health by 3.7% in the 2nd quarter. Wetherby Asset Management Inc. now owns 8,912 shares of the medical research company’s stock worth $290,000 after buying an additional 317 shares in the last quarter. Dubuque Bank & Trust Co. increased its holdings in Genomic Health by 8.4% in the 2nd quarter. Dubuque Bank & Trust Co. now owns 4,897 shares of the medical research company’s stock worth $159,000 after buying an additional 379 shares in the last quarter. Parametric Portfolio Associates LLC increased its holdings in Genomic Health by 5.8% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 8,051 shares of the medical research company’s stock worth $262,000 after buying an additional 441 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Genomic Health by 0.6% in the 1st quarter. Bank of New York Mellon Corp now owns 88,577 shares of the medical research company’s stock worth $2,789,000 after buying an additional 500 shares in the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in Genomic Health by 3.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,857 shares of the medical research company’s stock worth $516,000 after buying an additional 520 shares in the last quarter. Institutional investors own 88.91% of the company’s stock.

GHDX has been the topic of a number of research analyst reports. Jefferies Group LLC reissued a “hold” rating and issued a $33.00 price target on shares of Genomic Health in a report on Thursday. Canaccord Genuity cut their price target on shares of Genomic Health from $36.00 to $35.00 and set a “buy” rating on the stock in a report on Tuesday, August 15th. BidaskClub downgraded shares of Genomic Health from a “hold” rating to a “sell” rating in a report on Friday, August 4th. Piper Jaffray Companies reissued a “hold” rating and issued a $31.00 price target on shares of Genomic Health in a report on Thursday, August 3rd. Finally, Zacks Investment Research downgraded shares of Genomic Health from a “hold” rating to a “sell” rating in a report on Tuesday, August 1st. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and one has assigned a buy rating to the stock. Genomic Health presently has an average rating of “Hold” and an average target price of $32.00.

About Genomic Health

Genomic Health, Inc is a healthcare company that provides genomic-based diagnostic tests to personalize cancer treatment. The Company develops and commercializes genomic-based clinical laboratory services. The Company’s Oncotype IQ Genomic Intelligence Platform is consisted of its flagship line of Oncotype DX gene expression tests, as well as its Oncotype SEQ Liquid Select test.

Insider Buying and Selling by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply